Reticulon 4B (Nogo-B) is a novel regulator of hepatic fibrosis

Hepatology

Volumn 53, Issue 4, 2011, Pages 1306-1315

  Zhang, Dahai ^a   Utsumi, Teruo ^a   Huang, Hui Chun ^a   Gao, Lili ^a   Sangwung, Panjamaporn ^a   Chung, Chuhan ^a   Shibao, Kazunori ^b   Okamoto, Kohji ^b   Yamaguchi, Koji ^b   Groszmann, Roberto J ^a   Jozsef, Levente ^a   Hao, Zhengrong ^a   Sessa, William C ^a   Iwakiri, Yasuko ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN NOGO; PROTEIN NOGO A; PROTEIN NOGO B; REGULATOR PROTEIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CELL ISOLATION; CONTROLLED STUDY; EMBRYO; GENE DELETION; HUMAN; HUMAN TISSUE; IMMUNOSTIMULATION; KNOCKOUT MOUSE; LIVER; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; REGULATORY MECHANISM; SHAM PROCEDURE; SIGNAL TRANSDUCTION; STELLATE CELL; TISSUE SECTION; WILD TYPE;

ANIMALS; BILE DUCTS; HEPATIC STELLATE CELLS; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, KNOCKOUT; MYELIN PROTEINS; RATS; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 79953761444     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24200     Document Type: Article

References (27)

1. Oertle T, Schwab ME. Nogo and its paRTNers. Trends Cell Biol 2003; 13: 187-194.
2. Teng FY, Tang BL. Cell autonomous function of Nogo and reticulons: the emerging story at the endoplasmic reticulum. J Cell Physiol 2008; 216: 303-308.
3. Yang YS, Strittmatter SM. The reticulons: a family of proteins with diverse functions. Genome Biol 2007; 8: 234.
4. Yu J, Fernandez-Hernando C, Suarez Y, Schleicher M, Hao Z, Wright PL, et al. Reticulon 4B (Nogo-B) is necessary for macrophage infiltration and tissue repair. Proc Natl Acad Sci U S A 2009; 106: 17511-17516.
5. Acevedo L, Yu J, Erdjument-Bromage H, Miao RQ, Kim JE, Fulton D, et al. A new role for Nogo as a regulator of vascular remodeling. Nat Med 2004; 10: 382-388.
6. Paszkowiak JJ, Maloney SP, Kudo FA, Muto A, Teso D, Rutland RC, et al. Evidence supporting changes in Nogo-B levels as a marker of neointimal expansion but not adaptive arterial remodeling. Vascul Pharmacol 2007; 46: 293-301.
7. Rodriguez-Feo JA, Hellings WE, Verhoeven BAN, Moll FL, de Kleijn DPV, Prendergast J, et al. Low levels of Nogo-B in human carotid atherosclerotic plaques are associated with an atheromatous phenotype, restenosis, and stenosis severity. Arterioscler Thromb Vasc Biol 2007; 27: 1354-1360.
8. Bullard TA, Protack TL, Aguilar F, Bagwe S, Massey HT, Blaxall BC. Identification of Nogo as a novel indicator of heart failure. Physiol Genomics 2008; 32: 182-189.
9. Rockey D, Friedman S. Hepatic Fibrosis and Cirrhosis. 5th ed. New York: Elsevier Inc.; 2006.
10. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
11. Liu F. PCTA: a new player in TGF-beta signaling. Sci Signal 2008; 1:p e49.
12. Kim JE, Li S, GrandPre T, Qiu D, Strittmatter SM. Axon regeneration in young adult mice lacking Nogo-A/B. Neuron 2003; 38: 187-199.
13. Zheng B, Ho C, Li S, Keirstead H, Steward O, Tessier-Lavigne M. Lack of enhanced spinal regeneration in Nogo-deficient mice. Neuron 2003; 38: 213-224.
14. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997; 113: 255-264.
15. Soroka CJ, Mennone A, Hagey LR, Ballatori N, Boyer JL. Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis. HEPATOLOGY 2010; 51: 181-190.
16. Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med 2005; 117: 237-250.
17. Shibao K, Izumi H, Nakayama Y, Ohta R, Nagata N, Nomoto M, et al. Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer 2002; 94: 1939-1946.
18. Friedman SL, Roll FJ. Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan. Anal Biochem 1987; 161: 207-218.
19. Kruglov EA, Correa PR, Arora G, Yu J, Nathanson MH, Dranoff JA. Molecular basis for calcium signaling in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2007; 292: G975-G982.
20. Passino MA, Adams RA, Sikorski SL, Akassoglou K. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science 2007; 315: 1853-1856.
21. Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1074-G1081.
22. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172.
23. Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology 2001; 120: 975-983.
24. Kisseleva T, Brenner DA. Fibrogenesis of parenchymal organs. Proc Am Thorac Soc 2008; 5: 338-342.
25. Wakana Y, Koyama S, Nakajima K, Hatsuzawa K, Nagahama M, Tani K, et al. Reticulon 3 is involved in membrane trafficking between the endoplasmic reticulum and Golgi. Biochem Biophys Res Commun 2005; 334: 1198-1205.
26. Voeltz GK, Prinz WA, Shibata Y, Rist JM, Rapoport TA. A class of membrane proteins shaping the tubular endoplasmic reticulum. Cell 2006; 124: 573-586.
27. Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 2010; 53: 976-980.